Revolutionizing Treatment: Nexcella’s CAR-T NXC-201 Receives FDA Approval for U.S. Patient Dosing
Nexcella Announces Expansion of NXC-201 Studies in Relapsed/Refractory AL Amyloidosis About NEXICART-2 Clinical Trial Nexcella, Inc. has announced the expansion of the NEXICART-2 clinical trial to U.S. sites following clearance of the Investigational New Drug (IND) application. This decision comes after positive results from the initial study involving 72 patients who were previously dosed with…